IP Library Granted Patent US 7,427,600
Granted Patent B2
US 7,427,600 · App. 10/923,088 · Granted Sep 23, 2008

Active agent delivery systems and methods for protecting and administering active agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,427,600
App. No.
10/923,088
Granted
Sep 23, 2008
Kind
B2
Abstract

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Claims (8)

1. A method of treating inflammatory bowel disease comprising administering to a patient in need thereof an effective amount of a compound consisting of mesalamine covalently attached to a single amino acid selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof.

2. A compound consisting of mesalamine covalently attached to a single amino acid wherein said single amino acid is selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein the amino acid is Valine.

4. A pharmaceutical composition comprising:

a compound consisting of mesalamine covalently attached to a single amino acid selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4 , wherein said composition is an oral dosage form.

6. The pharmaceutical composition of claim 4 , wherein the compound is mesalamine covalently attached to Valine.

7. The method of claim 1 , wherein the compound is mesalamine covalently attached to Valine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2020
From: SHIRE LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 054626/0595 →
MERGER Recorded Nov 1, 2007
From: NEW RIVER PHARMACEUTICALS INC.
To: SHIRE LLC
Reel/Frame 020054/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2005
From: MICKLE, TRAVIS; MONCRIEF, JAMES SCOTT; KRISHNAN, SUMA; PICCARIELLO, THOMAS; LAUDERBACK, CHRISTOPHER; KIRK, RANDAL
To: NEW RIVER PHARMACEUTICALS INC.
Reel/Frame 016149/0009 →